Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Efficacy is just one of many factors that should be considered when choosing therapies for ...
Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback